Bortezomib is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bortezomib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bortezomib overview

Bortezomib (Velcade) is a dipeptide boronic acid analogue with anti-neoplastic activity. It is formulated as lyophilized powder for solution for intravenous or subcutaneous route of administration. Velcade is indicated for the treatment of multiple myeloma. The drug candidate is under development for the treatment of non-small cell lung cancer, diffuse large B-cell lymphoma, graft versus host disease, relapsed or refractory acute myelogenous leukemia, primary plasma cell leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome. The drug candidate was also under development for the treatment of B-cell lymphomas including marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma and follicular lymphoma, as first line therapy for non-cutaneous peripheral T-cell lymphoma, including human T-cell lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer (NK)-cell lymphoma, epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer, relapsed/refractory light chain amyloidosis, metastatic colorectal carcinoma, follicular non-Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, metastatic ductal adenocarcinoma of the pancreas, bronchioloalveolar carcinoma, metastatic breast cancer, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Waldenstrom macroglobulinemia and adenocarcinoma with bronchioloalveolar features.

Millennium Pharmaceuticals overview

Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Bortezomib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.